Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO102-IO103 plus pembrolizumab versus pembrolizumab alone in advanced melanoma
NL-OMON59641Phase 3Completed
- Sponsor
- IO Biotech
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in melanoma comparing IO102-IO103 plus pembrolizumab with Pembrolizumab alone (2 arms). Primary endpoint: Progression-free survival. Started Jul 2022; status: completed.
02
Drugs
PD-L1/IDO peptide vaccinepembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON59641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59641.